L-Asparaginase

Product: 
L-Asparaginase
Formalary: 
Specialty Formalary
Category: 
Oncology
Trade Name: 
Elspar, Kidrolase
Packing: 
Vial
Potency: 
5000KU, 10000KU, 10000IU
In Treatment of: 
Acute leukaemia, Malignant lymphoma.
Adverse Effects: 
The main side effect is an allergic or hypersensitivity reaction; anaphylaxis is a possibility. Asparaginase has also been associated with pancreatitis. Additionally, it can also be associated with a coagulopathy as it decreases protein synthesis, including synthesis of coagulation factors (eg progressive isolated decrease of fibrinogen) and anticoagulant factor (generally antithrombin III; sometimes protein C & S as well), leading to bleeding or thrombotic events such as stroke.
Contraindication: 
1. Hypersensitivity or previous serious allergic reaction (such as generalized urticaria, bronchospasm, laryngeal edema, hypotension) to drug. 2. Pancreatitis or history of pancreatitis. 3. Previous hemorrhagic events related to L-asparaginase therapy
Special Precaution: 
1. renal or hepatic disease, CNS disorders. 2. concurrent use of hepatotoxic agents, anticoagulants, aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) 3. pregnant or breastfeeding patients.
Interaction: 
Vincristine and prednisolone increases the toxicity, diminishes or abolishes the effect of methotrexate on malignant cells.
Dosages: 
50-200 k.u/kg body wt. daily or every alternate day by I.V infusion.

Share Us